期刊
CANCER TREATMENT REVIEWS
卷 69, 期 -, 页码 53-65出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2018.06.001
关键词
Epithelial ovarian cancer; Antiangiogenic agents; Maintenance therapy; Poly(adenosine diphosphate-ribose); polymerase (PARP) inhibitors; PARPi
类别
资金
- AstraZeneca LP (Wilmington, DE)
- Merck & Co., Inc. (Kenilworth, NJ)
Approximately 1% of women in the United States will be diagnosed with epithelial ovarian cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage, requiring aggressive therapeutic measures, and most women will succumb to this illness. Due to advancements in therapy, the oncology community has begun to shift its focus to molecular targeted agents, alternative dosing schedules, and maintenance therapy. Women who achieve a response to initial adjuvant chemotherapy may be candidates for maintenance therapy, with the goal of inducing a lasting remission or prolonging the disease-free interval before recurrence. The rationale for maintenance therapy is to delay disease progression by eliminating residual, slowly-dying cancerous cells, or impeding cell turnover. This review discusses the goals of maintenance therapy for EOC with antiangiogenic agents or poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, and reviews clinical studies that have demonstrated improvements in survival outcomes. The side-effect profiles for PARP inhibitors and the implications for preserving quality of life during maintenance therapy will also be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据